Mundipharma licenses Starpharmas VivaGel BV
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Appendix 4C - Quarterly Cashflow Report
- Starpharma completes US New Drug Application for VivaGel BV
- Starpharma receives $3.7M R&D tax incentive refund
- Starpharma to commence DEP cabazitaxel phase 1/2 trial
- VivaGel BV treatment clinical submission under rolling NDA
Later from Starpharma
- Starpharma licenses VivaGel BV to Mundipharma for Europe
- VivaGel BV NDA advances to next stage of FDA review
- Annual report and full year financial results
- AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
- DEP irinotecan outperforms in pancreatic cancer model
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma